Mithra Pharmaceuticals S.A.

Regulatory Filings • Oct 30, 2023

CONFIDENTIAL DRAFT

Mithra Announces Temporary Trading Halt for the Duration of Today's Special and Extraordinary General Meetings

Liege, Belgium, 30 October 2023 -13:40 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA) (the "Company" or "Mithra"), a company dedicated to Women's Health, announces that, in view of its Special General Meetings (SGM) and Extraordinary General Meeting (EGM) that will be held today around 14:00 CET, it has requested the Belgian Financial Services and Markets Authority (FSMA) to temporarily halt the trading of the Company's shares on Euronext Brussels for the duration of the General Meetings.

Trading of the Company's shares on Euronext Brussels has been temporarily halted today, as from ca. 1:30 p.m. CET, and will resume after the announcement by the Company of the results of the General Meetings.

For more information, please contact:

Mithra Pharmaceuticals SA

Alex Sokolowski, PhD	Frédérique Depraetere
Head of Investor Relations	Communications Director
investorrelations@mithra.com	info@mithra.com
+32 (0)4 349 28 22	+32 (0)4 349 28 22

About Mithra

Mithra Pharmaceuticals SA (Euronext: MITRA) is a Belgian biopharmaceutical company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill ESTELLE® , Mithra is now focusing on its second product DONESTA® , the next-generation hormone therapy. Mithra also offers partners a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals (vials, pre-filled syringes or cartridges) at its technological platform Mithra CDMO. Active in more than 100 countries around the world, is headquartered in Liège, Belgium. www.mithra.com

ESTELLE® and DONESTA® are registered trademarks of Mithra Pharmaceuticals or one of its affiliates.

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes CONFIDENTIAL DRAFT

concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

News Alerts

Subscribe to our mailing list on investors.mithra.com to receive press releases by email or follow us on social media: Linkedin • X • Facebook